热疗联合肝脾双介入治疗Ⅲ期原发性肝癌患者的临床效果分析  

Analysis of Clinical Effect of Thermotherapy Combined with Liver Spleen Double Interventional Therapy in Patients with StageⅢPrimary Liver Cancer

作　　者：郭双 尹承龙 黄东彬 梁梅兴 Guo Shuang;Yin Cheng-long;Huang Dong-bin;Liang Mei-xing(Department of Oncology,The People's Hospital of Jiangmen,Jiangmen 529000,Guangdong Province,China)

机构地区：[1]江门市人民医院肿瘤科,广东江门529000

出　　处：《中国社区医师》2023年第9期25-27,共3页Chinese Community Doctors

基　　金：江门市科技计划项目(编号:2020020100840002912,2021YL02002)。

摘　　要：目的:探讨热疗联合肝脾双介入治疗Ⅲ期原发性肝癌患者的临床效果。方法:选取2020年2月—2021年12月江门市人民医院肿瘤科收治的30例Ⅲ期原发性肝癌患者作为研究对象,根据随机数字表法分为对照组与研究组,各15例。对照组给予肝动脉化疗栓塞术治疗,研究组给予热疗联合肝脾双介入治疗。比较两组患者疾病控制率、不良反应发生情况、血清肿瘤标志物水平、生活质量评分。结果:两组患者疾病控制率比较,差异无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,两组患者血清甲胎蛋白水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者生理、心理、环境、社会关系评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。结论:对Ⅲ期原发性肝癌患者采用热疗联合肝脾双介入治疗可增强近期疗效,控制肿瘤进展,提升患者生活质量,且不良反应少。Objective:To explore the clinical effect of thermotherapy combined with liver and spleen double interventional therapy in the patients with stageⅢprimary liver cancer.Methods:A total of 30 patients with stageⅢprimary liver cancer admitted to Department of Oncology of the People's Hospital of Jiangmen from February 2020 to December 2021 were collected as the study subjects.They were divided into control group and study group according to random number table method,with 15 cases in each group.The control group was treated with hepatic artery chemoembolization,and the study group was treated with thermotherapy combined with liver and spleen double intervention.The disease control rate,adverse reactions,levels of serum tumor markers and quality of life score were compared between the two groups.Results:There was no significant difference in disease control rates be⁃tween the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the serum alpha-fetoprotein level in the two groups was lower than that that before treatment,and the study group was lower than the control group,and the difference was statistically significant(P<0.05).After treatment,the physi⁃cal,psychological,environmental and social relationship scores in the two groups were higher than those before treatment,and the study group was higher than the control group,and the difference was statistically significant(P<0.05).Conclusion:For stageⅢprimary liver cancer patients,thermotherapy combined with liver spleen double interventional therapy can enhance the short-term efficacy,control tumor progression,improve quality of life,and have fewer adverse reactions.

关 键 词：原发性肝癌 肝动脉化疗栓塞术 热疗 肝脾双介入 

分 类 号：R735.7[医药卫生—肿瘤]